Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol To FDA For Comment (Medical News Today)
Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S. Food and Drug Administration's (the "FDA") Division of Cardiovascular and Renal Products.

Vanda Pharma Sinks on FDA Rejection (TheStreet.com)
Its lead drug, antipsychotic iloperidone, will require another clinical trial and more safety data before approval.